2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD

Despite remarkable progresses in the definition of cellular, biochemical and molecular biology pathways in the pathogenesis of Severe Asthma, Chronic Obstructive Pulmonary Disorder (COPD) and Interstitial Lung Disorders (ILDs), there is still a substantial unmet need for new drugs able to control and/or change the natural history of these diseases. This Seminar intended to underline the key role of a side-to-side collaboration between clinicians, scientists, bioinformaticians and statisticians in the comprehension of pathological processes underlying different respiratory disorders. It provided a framework to improve the ability to identify potential pharmacological targets for the development of innovative drugs.

2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD

2023 - In Vitro Diagnostic (IVD) tests to combat antimicrobial resistance in community-acquired low-respiratory tract infections (CA-LRTI)

2024 - Sleep apnea and its consequences: from animal models to precision medicine

2019 - New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

Characterisation of clinical phenotypes is mandatory for the development of new drugs

N. Roche (Paris, France)

Slides

Asthma and COPD: similarities and differences in pathogenesis

A. Di Stefano (Veruno, Italy)

Slides

Accompanying documents

Bioinformatic tools for systems medicine in allergy

M. Benson (Linköping, Sweden)

Slides

Accompanying documents

Human translational medicine phenotyping is key

R. Djukanovic (Southampton, United Kingdom)

Accompanying documents

Lipidomic phenotyping of severe asthma

J. Brandsma (Southampton, United Kingdom)

Slides

New drugs for severe asthma what should we target and how?

K.F. Chung (London, United Kingdom)

Slides

Accompanying documents

Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation

L. Uller (Lund, Sweden)

Slides

Accompanying documents

Developing integrated handprints of severe asthma: the U-BIOPRED approach

B. De Meulder (Lyon, France)

Slides

Human translational medicine in ILD: the promise of new drugs

O. Eickelberg (Munich, Germany)

Accompanying documents

New Drugs for COPD: the current status

I. Adcock (London, United Kingdom)

Slides

Accompanying documents

COPD will new insights into molecular pathology define new therapies?

C. Greene (Dublin, Ireland)

Slides

Accompanying documents

What are the knowledge gaps in COPD that prevent new drug development?

G. Caramori (Ferrara, Italy)

Accompanying documents

Chaperonins in COPD

F. Cappello (Palermo, Italy)

Slides

2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD

2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD

#{title}